Table 1.

Inclusion and Exclusion Criteria for Nested Case Control Study

Inclusion Criteria	Exclusion Criteria
1. Diagnosis of primary lung cancer 2. Seen at Mayo Clinic for primary lung cancer between 1997 and 2006 3. Primary lung cancer pathology confirmed by Mayo Clinic pathologist 4. Received at least one dose of platinum (Cisplatin, Carboplatin) for primary lung cancer 5.Genotyped for SNPs on peripheral whole blood 6.Consented for use of medical records and study participation	1. Toxicity data not available throughout and after all platinum chemotherapy 2.CIPN developed greater than 6 months after last dose of platinum chemotherapy 3.Unclear or uncommon CIPN Symptoms noted (i.e. not primarily sensory neuropathy, significant motor deficit, not primarily stocking and glove distribution, etc) and excluded by the neurologists on our study team